BridgeBio Pharma BBIO Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's total liabilities & equity?
- BridgeBio Pharma (BBIO) reported total liabilities & equity of $1.37B in Q1 2026.
- How has BridgeBio Pharma's total liabilities & equity changed year-over-year?
- BridgeBio Pharma's total liabilities & equity increased by 55.5% year-over-year, from $881.64M to $1.37B.
- What is the long-term trend for BridgeBio Pharma's total liabilities & equity?
- Over 5 years (2020 to 2025), BridgeBio Pharma's total liabilities & equity has grown at a 5.9% compound annual growth rate (CAGR), from $703.59M to $936.03M.
- What does total liabilities & equity mean?
- The total value of all liabilities and equity, which must equal the company's total assets.
- How do you interpret total liabilities & equity?
- An increase generally signals growth in the company's asset base funded by either debt or equity issuance, while a decrease may signal asset liquidation or debt repayment.
- How does total liabilities & equity compare across companies?
- Standard across all public companies; used as the denominator for calculating various return ratios and leverage metrics across the biotech sector.